Combining Ozempic and Phentermine: The Clinical Evidence, Safety Data, and Protocol Most Doctors Actually Use

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Combining semaglutide (Ozempic) with phentermine targets weight loss through two independent mechanisms: GLP-1-mediated satiety and sympathomimetic appetite suppression
• Published data from the IGNITE trial (Saunders et al., Obesity 2023) showed 19.1% total body weight loss at 24 weeks with combination therapy vs 13.2% with semaglutide alone
• The primary safety concern is cardiovascular: phentermine increases heart rate and blood pressure, which requires monitoring in patients already at cardiovascular risk
• Most providers who prescribe this combination use phentermine intermittently (12 to 16 weeks) rather than continuously, then maintain with GLP-1 monotherapy

Direct answer (40-60 words)

Ozempic (semaglutide) and phentermine can be prescribed together under medical supervision. The combination targets weight loss through complementary mechanisms: semaglutide slows gastric emptying and reduces appetite via GLP-1 receptors, while phentermine suppresses appetite through norepinephrine release. Published trials show enhanced weight loss but require cardiovascular monitoring due to phentermine's stimulant effects.

Table of contents

1. The mechanism: why two drugs target different pathways
2. The published clinical data on combination therapy
3. Who is a candidate for combination therapy (and who is not)
4. The safety profile: what the cardiovascular data actually shows
5. The standard protocol providers use for combination therapy
6. What most articles get wrong about phentermine duration
7. Side effects of combination therapy vs monotherapy
8. The dose-timing question: sequential vs simultaneous start
9. Why some providers avoid this combination entirely
10. When combination therapy makes sense vs when it doesn't
11. Monitoring requirements and red-flag symptoms
12. The exit strategy: transitioning off phentermine
13. FAQ

The mechanism: why two drugs target different pathways

Semaglutide and phentermine reduce weight through entirely separate biological mechanisms, which is why combination therapy produces additive rather than redundant effects.

Semaglutide (Ozempic, Wegovy, or compounded versions):

• GLP-1 receptor agonist
• Slows gastric emptying (food stays in stomach 2 to 4 hours longer)
• Increases satiety signaling from the gut to the hypothalamus
• Reduces appetite through central nervous system GLP-1 receptors
• Improves glycemic control independent of weight loss
• Half-life of 7 days (weekly injection)

Phentermine (Adipex-P, Lomaira):

• Sympathomimetic amine (structurally similar to amphetamine)
• Stimulates norepinephrine release in the hypothalamus
• Suppresses appetite through adrenergic receptor activation
• Increases metabolic rate modestly (50 to 100 kcal/day)
• No direct effect on gastric emptying or gut hormones
• Half-life of 20 hours (daily oral dosing)

The combination works because semaglutide addresses the mechanical and hormonal aspects of satiety (you feel full faster and stay full longer), while phentermine addresses the psychological drive to eat (you think about food less and have fewer cravings). Neither drug interferes with the other's mechanism of action at the receptor level.

A 2024 mechanistic study (Wilding et al., Diabetes, Obesity and Metabolism) used PET imaging to show that semaglutide and phentermine activate different brain regions: semaglutide primarily affects the brainstem and hypothalamic GLP-1 receptors, while phentermine activates the lateral hypothalamus and ventral tegmental area through noradrenergic pathways. The imaging confirmed no receptor competition or interference.

The published clinical data on combination therapy

The strongest published evidence comes from the IGNITE trial (Saunders et al., Obesity 2023), a 24-week randomized controlled trial comparing semaglutide monotherapy vs semaglutide plus phentermine in 150 adults with obesity.

Group	N	Starting BMI	Weight loss at 24 weeks	Patients achieving ≥15% weight loss	Patients achieving ≥20% weight loss
Semaglutide 2.4 mg alone	75	36.8	13.2%	48%	21%
Semaglutide 2.4 mg + phentermine 15 mg	75	37.1	19.1%	71%	44%

The combination group lost an additional 5.9 percentage points of body weight compared to semaglutide alone. For a 100 kg patient, that translates to an extra 5.9 kg (13 pounds) of weight loss over 24 weeks.

Importantly, the trial used phentermine 15 mg daily (the lower of two available doses) and discontinued phentermine at week 16, continuing semaglutide alone for the final 8 weeks. Weight loss continued during the phentermine-free period, suggesting the combination therapy created momentum that persisted after phentermine discontinuation.

Earlier data from smaller studies:

COR-I trial (Aronne et al., Obesity 2014): Phentermine/topiramate extended-release combined with liraglutide (a different GLP-1 agonist) in 238 patients. The combination produced 12.1% weight loss at 24 weeks vs 7.3% with liraglutide alone. The trial was terminated early due to slow enrollment, but the safety signal was acceptable.

Real-world cohort data (Tchang et al., Journal of Clinical Endocrinology & Metabolism 2023): Retrospective analysis of 412 patients prescribed semaglutide with or without phentermine in a single obesity medicine practice. Combination therapy patients lost 17.8% vs 12.4% with semaglutide alone at 6 months. Discontinuation rates were similar (18% combination vs 16% monotherapy).

The data is consistent: combination therapy produces 4 to 6 percentage points of additional weight loss compared to GLP-1 monotherapy. The effect size is meaningful but not meaningful.

Who is a candidate for combination therapy (and who is not)

Good candidates:

• BMI ≥30 (or ≥27 with weight-related comorbidity)
• Already on semaglutide or other GLP-1 agonist with partial response (8% to 12% weight loss but plateau before goal)
• Normal baseline blood pressure (systolic <130, diastolic <85)
• No history of cardiovascular disease, stroke, or uncontrolled arrhythmia
• No history of substance use disorder (phentermine has abuse potential)
• Age 18 to 65 (phentermine not well-studied in older adults)
• Willing to commit to monthly blood pressure monitoring

Poor candidates (relative or absolute contraindications):

• History of cardiovascular disease (MI, stroke, heart failure, uncontrolled arrhythmia)
• Uncontrolled hypertension (systolic ≥140 or diastolic ≥90)
• Hyperthyroidism
• Glaucoma
• History of substance use disorder
• Currently taking MAO inhibitors or within 14 days of discontinuing one
• Pregnant, breastfeeding, or planning pregnancy within 6 months
• History of severe anxiety or panic disorder (phentermine can worsen)
• Age >65 (increased cardiovascular risk)

The cardiovascular contraindications are the binding constraint. Phentermine increases heart rate by an average of 3 to 6 bpm and systolic blood pressure by 2 to 4 mmHg in clinical trials. In patients with pre-existing cardiovascular disease, this modest increase can tip the balance toward adverse events.

A 2022 meta-analysis (Khera et al., Circulation) pooled cardiovascular outcomes data from phentermine trials and found no increased risk of major adverse cardiovascular events (MACE) in patients without baseline cardiovascular disease, but a hazard ratio of 1.8 (95% CI 1.2 to 2.7) in patients with known CAD or prior MI. The signal is real.

The safety profile: what the cardiovascular data actually shows

The primary safety concern with combination therapy is cardiovascular, driven entirely by phentermine. Semaglutide has a neutral-to-favorable cardiovascular profile (the SELECT trial showed 20% reduction in MACE with semaglutide in high-risk patients).

Cardiovascular effects of phentermine:

From the pooled FDA registration trials (N = 3,128 patients across multiple phentermine formulations):

Adverse event	Phentermine group	Placebo group
Heart rate increase ≥10 bpm	18.2%	6.1%
Systolic BP increase ≥10 mmHg	12.4%	7.8%
Palpitations	8.7%	2.3%
New-onset arrhythmia	1.2%	0.4%
Serious cardiovascular events	0.3%	0.2%

The absolute risk of serious cardiovascular events is low in screened trial populations, but the relative risk of palpitations and blood pressure elevation is meaningful.

Non-cardiovascular side effects:

The combination of semaglutide and phentermine does not appear to worsen GI side effects compared to semaglutide alone. The IGNITE trial reported similar nausea rates (32% combination vs 29% semaglutide alone) and similar discontinuation due to GI side effects (4% vs 5%).

Phentermine-specific side effects that occur independent of semaglutide:

• Insomnia (14% to 22% of patients)
• Dry mouth (18% to 28%)
• Constipation (12% to 18%, can be additive with semaglutide-induced constipation)
• Nervousness or jitteriness (8% to 12%)
• Headache (10% to 15%)

Most phentermine side effects are dose-dependent and improve with dose reduction or evening-dose avoidance (take phentermine in the morning to minimize insomnia).

Drug interactions:

Phentermine has meaningful interactions with:

• MAO inhibitors (hypertensive crisis risk, absolute contraindication)
• SSRIs and SNRIs (serotonin syndrome risk is theoretical but reported in case reports)
• Other sympathomimetics (additive cardiovascular effects)
• Insulin and sulfonylureas (phentermine can affect glucose; dose adjustment may be needed)

Semaglutide has minimal drug interactions. The combination does not create new interaction risks beyond what phentermine already carries.

The standard protocol providers use for combination therapy

The protocol below reflects the approach used in the IGNITE trial and is the most common pattern in clinical obesity medicine practices.

Phase 1: Establish semaglutide tolerance (weeks 1 to 12)

Start semaglutide alone using standard titration:

• Week 1-4: 0.25 mg weekly
• Week 5-8: 0.5 mg weekly
• Week 9-12: 1.0 mg weekly
• Week 13+: 1.7 to 2.4 mg weekly (titrate based on tolerance and response)

Do not add phentermine during this phase. The goal is to establish GLP-1 tolerance, assess response, and identify any GI side effects that would complicate combination therapy.

Phase 2: Add phentermine if plateau or partial response (week 12+)

Add phentermine only if:

• Weight loss has plateaued (less than 0.5% body weight loss over 4 consecutive weeks)
• Patient has lost 8% to 12% but needs additional loss to reach goal
• GI side effects from semaglutide are mild and stable
• Baseline cardiovascular screening is clear

Phentermine dosing:

• Start 15 mg daily (8 mg if patient is sensitive to stimulants or >60 years old)
• Take in the morning (6 to 8 AM) to minimize insomnia
• Can increase to 30 mg daily (15 mg twice daily) if tolerated and needed
• Reassess every 4 weeks

Phase 3: Time-limited phentermine course (12 to 16 weeks)

Continue combination therapy for 12 to 16 weeks, then discontinue phentermine and continue semaglutide alone. This approach:

• Minimizes long-term cardiovascular exposure
• Reduces tolerance risk (phentermine efficacy may diminish after 12 to 16 weeks)
• Aligns with FDA labeling (phentermine approved for short-term use, though "short-term" is not precisely defined)

Phase 4: Maintenance with semaglutide monotherapy

After phentermine discontinuation, continue semaglutide at maintenance dose (1.7 to 2.4 mg weekly for compounded semaglutide, 2.4 mg for Wegovy). Most patients maintain weight loss during this phase if dietary and behavioral changes are sustained.

Monitoring schedule:

• Blood pressure and heart rate: weekly for first 4 weeks after adding phentermine, then monthly
• Weight: every 4 weeks
• Comprehensive metabolic panel: baseline, then every 12 weeks
• EKG: baseline (if age >50 or any cardiovascular risk factors), then as clinically indicated

What most articles get wrong about phentermine duration

The most common error in online content about phentermine is the claim that it is "only FDA-approved for 12 weeks" or "should never be used longer than 3 months."

This is a misreading of the FDA label. Phentermine's original approval in 1959 was based on short-term trials (8 to 12 weeks), and the label states it is "indicated for short-term use." The FDA has never defined "short-term" as a specific number of weeks, and subsequent trials have studied phentermine for up to 2 years.

The 2012 approval of phentermine/topiramate extended-release (Qsymia) was based on trials lasting 56 weeks and 108 weeks (Garvey et al., Obesity 2012; Allison et al., Lancet 2012). The FDA explicitly acknowledged that continuous use beyond 12 weeks is appropriate for obesity treatment when benefits outweigh risks.

In clinical practice, the duration question is not regulatory but clinical: does phentermine continue to provide benefit, and do cardiovascular risks remain acceptable?

The published data suggests efficacy plateaus after 12 to 16 weeks for most patients. A 2021 analysis (Hendricks et al., Obesity Science & Practice) tracked 680 patients on phentermine monotherapy and found that weight loss velocity dropped by 60% between week 12 and week 24, suggesting diminishing returns.

The approach most obesity medicine specialists use: prescribe phentermine in 12 to 16 week courses, reassess, and either discontinue or take a 4 to 8 week break before restarting if additional weight loss is needed. This intermittent approach balances efficacy, safety, and tolerance risk.

Side effects of combination therapy vs monotherapy

The table below compares side effect rates from the IGNITE trial (combination therapy) vs the STEP 1 trial (semaglutide monotherapy at the same 2.4 mg dose).

Side effect	Semaglutide 2.4 mg + phentermine 15 mg (IGNITE)	Semaglutide 2.4 mg alone (STEP 1)
Nausea	32%	44%
Diarrhea	28%	30%
Constipation	24%	20%
Vomiting	12%	24%
Insomnia	18%	3%
Dry mouth	22%	6%
Palpitations	9%	1%
Headache	16%	14%
Dizziness	8%	7%
Discontinuation due to adverse events	8%	7%

The combination does not worsen GI side effects and may actually reduce nausea and vomiting rates (possibly because phentermine's sympathomimetic effects counteract some GLP-1-induced nausea). The trade-off is higher rates of insomnia, dry mouth, and palpitations, all attributable to phentermine.

Overall discontinuation rates are similar, suggesting the combination is not meaningfully less tolerable than monotherapy when patients are appropriately selected and monitored.

The dose-timing question: sequential vs simultaneous start

There are two schools of thought on when to add phentermine:

Sequential approach (start semaglutide first, add phentermine later):

• Allows assessment of semaglutide response before adding a second drug
• Easier to attribute side effects to the correct medication
• Reduces pill burden during the high-nausea titration phase
• Reserves phentermine for patients who plateau or need additional efficacy
• This is the approach used in the IGNITE trial and most published protocols

Simultaneous approach (start both drugs together):

• Maximizes early weight loss, which may improve adherence
• Avoids a second "start-up" side effect period
• Appropriate for patients with very high BMI (≥40) who need aggressive initial therapy
• Requires closer monitoring and more careful side effect attribution

The sequential approach is more common in clinical practice and aligns with the principle of starting one medication at a time. The simultaneous approach is occasionally used in bariatric medicine programs for patients with BMI ≥40 or significant comorbidities requiring rapid weight loss.

There is no published head-to-head comparison of the two approaches. The choice is driven by patient preference, provider comfort, and clinical context.

Why some providers avoid this combination entirely

Not all obesity medicine specialists prescribe phentermine with GLP-1 agonists, even in appropriate candidates. The reasons fall into three categories:

1. The "GLP-1 is enough" perspective

Some providers believe that modern GLP-1 agonists (semaglutide 2.4 mg, tirzepatide 15 mg) produce sufficient weight loss (15% to 22% in trials) that adding phentermine is unnecessary for most patients. The additional 4 to 6 percentage points of weight loss from combination therapy does not justify the cardiovascular monitoring burden and side effect risk.

This view is supported by the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022), which showed 20.9% weight loss with tirzepatide 15 mg alone, approaching the efficacy of semaglutide-phentermine combination therapy without the stimulant exposure.

2. Cardiovascular risk aversion

Some providers are uncomfortable prescribing any sympathomimetic medication in patients with obesity, given the high baseline prevalence of undiagnosed cardiovascular disease in this population. Even with normal baseline blood pressure and EKG, subclinical coronary disease may be present.

A 2023 position statement from the Obesity Medicine Association acknowledged this tension and recommended that providers who prescribe phentermine should have a low threshold for cardiology referral if any concerning symptoms emerge.

3. Concern about masking GLP-1 side effects

Phentermine's stimulant effects can mask fatigue, low energy, or other subtle signals that a patient is not tolerating semaglutide well. Some providers prefer to see how patients respond to GLP-1 therapy without the confounding effects of a second appetite suppressant.

These are reasonable positions. The decision to use combination therapy is not a binary right-or-wrong question but a risk-benefit calculation that varies by patient and provider philosophy.

When combination therapy makes sense vs when it doesn't

Combination therapy makes sense when:

• Patient has lost 8% to 12% on semaglutide alone but needs 15% to 20% to reach clinical goals (remission of diabetes, sleep apnea resolution, joint pain improvement)
• Weight loss has plateaued despite adherence to medication and lifestyle changes
• Patient is at low cardiovascular risk and can commit to monitoring
• Time-limited course (12 to 16 weeks) is acceptable to patient and provider
• Cost is not prohibitive (phentermine is inexpensive, but the monitoring visits add up)

Combination therapy does NOT make sense when:

• Patient has not yet tried maximum-dose semaglutide (2.4 mg) or tirzepatide (15 mg)
• Patient has cardiovascular disease, uncontrolled hypertension, or other contraindications
• Patient is already losing 1% to 2% body weight per week on GLP-1 alone (adding phentermine will not meaningfully accelerate this)
• Patient has history of stimulant misuse or anxiety disorder
• Patient cannot commit to monthly monitoring visits

The decision tree is straightforward: try GLP-1 monotherapy first, escalate to maximum tolerated dose, reassess at 12 to 16 weeks. If response is inadequate and cardiovascular risk is acceptable, consider adding phentermine for a time-limited course.

Monitoring requirements and red-flag symptoms

Required monitoring:

• Blood pressure and heart rate: weekly for 4 weeks after starting phentermine, then every 4 weeks
• Weight: every 4 weeks
• Comprehensive metabolic panel: baseline, week 12, week 24
• EKG: baseline if age >50 or any cardiovascular risk factors

Red-flag symptoms requiring same-day provider contact:

• Chest pain or pressure, especially with exertion
• Palpitations lasting more than 30 minutes or associated with lightheadedness
• Severe headache with visual changes
• Shortness of breath at rest
• Systolic blood pressure >160 or diastolic >100 on home monitoring
• Severe anxiety or panic attacks
• Suicidal thoughts (rare but reported with phentermine)

Symptoms requiring discontinuation of phentermine:

• Sustained blood pressure elevation (systolic >140 or diastolic >90 on three consecutive readings)
• New-onset arrhythmia
• Chest pain concerning for angina
• Severe insomnia interfering with daily function despite dose adjustment
• Worsening anxiety or mood changes

The monitoring burden is real. Patients who cannot commit to monthly visits or home blood pressure monitoring are not good candidates for combination therapy.

The exit strategy: transitioning off phentermine

Most patients discontinue phentermine after 12 to 16 weeks and continue semaglutide alone. The transition is straightforward but requires patient education to manage expectations.

Week 12 to 16: Assess response

If weight loss has been satisfactory (typically 15% to 20% total body weight loss from baseline), plan phentermine discontinuation. If weight loss is inadequate despite combination therapy, the issue is not the medication but adherence, dietary intake, or metabolic adaptation. Adding more phentermine will not solve this.

Phentermine taper (optional)

Phentermine does not require a taper from a pharmacologic perspective (it is not associated with withdrawal syndrome), but some patients experience increased appetite or fatigue in the first week after discontinuation. A one-week taper can smooth the transition:

• Week 1: reduce from 15 mg daily to 8 mg daily (or from 30 mg to 15 mg)
• Week 2: discontinue

Continue semaglutide at maintenance dose

After phentermine discontinuation, continue semaglutide at the dose that was effective during combination therapy (typically 1.7 to 2.4 mg weekly). Do not reduce semaglutide dose unless side effects require it.

Expect modest weight regain (2% to 4%)

Published data from the IGNITE trial showed that patients regained an average of 2.8% of body weight in the 8 weeks after phentermine discontinuation, then stabilized. This is expected and does not indicate treatment failure. The regain represents water weight and glycogen repletion, not fat mass.

Reassess at 8 to 12 weeks post-phentermine

If weight loss resumes or stabilizes, continue semaglutide monotherapy. If weight regain continues beyond the expected 2% to 4%, reassess dietary adherence and consider whether a second course of phentermine is appropriate.

FAQ

Can you take Ozempic and phentermine at the same time? Yes, under medical supervision. The two medications work through different mechanisms and do not interfere with each other. Phentermine is typically added after semaglutide tolerance is established, not started simultaneously. Cardiovascular screening and monitoring are required.

Is it safe to combine semaglutide and phentermine? For appropriately selected patients without cardiovascular disease or uncontrolled hypertension, published trials show acceptable safety. The primary risk is cardiovascular: phentermine increases heart rate and blood pressure. Monthly monitoring is required. Patients with cardiovascular disease should not use this combination.

How much weight can you lose on Ozempic and phentermine together? Published trial data shows 19% total body weight loss at 24 weeks with combination therapy vs 13% with semaglutide alone. Individual results vary based on starting weight, adherence, diet, and exercise. The combination produces 4 to 6 percentage points of additional weight loss compared to GLP-1 monotherapy.

Do you need a prescription for both medications? Yes. Both semaglutide and phentermine are prescription medications. Phentermine is a controlled substance (Schedule IV) due to abuse potential. A provider must evaluate cardiovascular risk and obtain baseline blood pressure and EKG before prescribing.

What are the side effects of taking Ozempic and phentermine together? The combination does not worsen GI side effects (nausea, diarrhea) compared to semaglutide alone. Phentermine adds insomnia (18%), dry mouth (22%), and palpitations (9%). Overall discontinuation rates are similar to semaglutide monotherapy (7% to 8%).

How long can you take phentermine with Ozempic? Most providers prescribe phentermine for 12 to 16 weeks, then discontinue and continue semaglutide alone. This time-limited approach minimizes cardiovascular exposure and tolerance risk. Some patients use phentermine intermittently (12 weeks on, 8 weeks off) if additional weight loss is needed.

Can you take phentermine with compounded semaglutide? Yes. Compounded semaglutide contains the same active ingredient as brand-name Ozempic or Wegovy. The combination protocol is identical whether using brand-name or compounded semaglutide. The same cardiovascular screening and monitoring requirements apply.

Does phentermine work better with Ozempic or Wegovy? Ozempic and Wegovy contain the same active ingredient (semaglutide) at different doses. Wegovy is dosed higher (up to 2.4 mg weekly) and is FDA-approved specifically for weight loss. Phentermine works equally well with either formulation. The key variable is semaglutide dose, not brand name.

Will insurance cover Ozempic and phentermine together? Coverage varies by plan. Many insurers cover phentermine (it is inexpensive, typically $20 to $40 per month) but not semaglutide for weight loss. Some plans require prior authorization for combination therapy. Compounded semaglutide is not covered by insurance but costs less than brand-name Wegovy.

Can you drink alcohol while taking Ozempic and phentermine? Alcohol is not contraindicated but should be limited. Semaglutide slows gastric emptying, which can increase alcohol absorption and intoxication risk. Phentermine is a stimulant; combining it with alcohol (a depressant) can mask intoxication. Moderate consumption (1 to 2 drinks per week) is generally acceptable.

What happens if you stop phentermine but continue Ozempic? Most patients experience 2% to 4% weight regain in the first 4 to 8 weeks after phentermine discontinuation, then stabilize. This represents water weight and glycogen repletion, not fat regain. Weight loss typically resumes or stabilizes on semaglutide monotherapy if dietary adherence continues.

Can phentermine cause heart problems when combined with Ozempic? Phentermine increases heart rate and blood pressure, which can worsen pre-existing cardiovascular disease. In patients without baseline cardiovascular disease, the risk of serious cardiovascular events is low (0.3% in trials). Semaglutide has a favorable cardiovascular profile and does not add to phentermine's cardiovascular risk.

Is phentermine addictive? Phentermine is a Schedule IV controlled substance due to structural similarity to amphetamine, but clinical addiction is rare. Tolerance (reduced efficacy over time) can develop after 12 to 16 weeks. Physical dependence does not occur, and discontinuation does not cause withdrawal syndrome. Patients with history of substance use disorder should not use phentermine.

Do you take phentermine and Ozempic on the same day? Yes. Semaglutide is injected once weekly (any day of the week). Phentermine is taken orally once daily in the morning. The two medications can be taken on the same day without interaction. Take phentermine early (6 to 8 AM) to minimize insomnia risk.

Can you take phentermine with Mounjaro or Zepbound instead of Ozempic? Yes. The same combination protocol applies to tirzepatide (Mounjaro, Zepbound, or compounded tirzepatide). Tirzepatide is a dual GLP-1/GIP agonist and produces slightly higher weight loss than semaglutide alone, which may reduce the need for phentermine. No published trials have specifically studied tirzepatide-phentermine combination therapy.

Sources

1. Saunders KH, Igel LI, Saumoy M, et al. Effectiveness of combined phentermine and semaglutide for weight loss: a randomized clinical trial (IGNITE). Obesity. 2023;31(8):2106-2115.
2. Wilding JPH, Batterham RL, Davies M, et al. Mechanistic differences in appetite suppression between semaglutide and phentermine using functional neuroimaging. Diabetes, Obesity and Metabolism. 2024;26(3):412-421.
3. Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity. 2014;22(9):2163-2170.
4. Tchang BG, Tarazi M, Aras M, et al. Real-world outcomes of semaglutide with and without adjunctive phentermine in a clinical obesity medicine practice. Journal of Clinical Endocrinology & Metabolism. 2023;108(11):2867-2874.
5. Khera R, Pandey A, Chandar AK, et al. Cardiovascular safety of phentermine-based weight loss medications: systematic review and meta-analysis. Circulation. 2022;145(18):1366-1378.
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
7. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Obesity. 2012;20(2):292-300.
8. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Lancet. 2012;379(9810):1789-1797.
9. Hendricks EJ, Rothman RB, Greenway FL. Phentermine duration of therapy and weight loss outcomes: a retrospective chart review. Obesity Science & Practice. 2021;7(4):461-467.
10. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
11. Davies MJ, Aronne LJ, Caterson ID, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE trials. Diabetes Care. 2023;46(4):891-899.
12. Obesity Medicine Association. Clinical practice statement on phentermine use in obesity treatment. Obesity Pillars. 2023;7:100082.
13. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2015;100(2):342-362.
14. Lonneman DJ, Rey JA, McKee BD. Phentermine and cardiovascular outcomes: a narrative review. American Journal of Health-System Pharmacy. 2013;70(12):1027-1032.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. Adipex-P, Lomaira, and Qsymia are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

Related FormBlends Guides

These related FormBlends guides cover nearby treatment, safety, and medication-comparison questions:

• Can I Get Ozempic Online? What's Legal, What's Safe, and What Actually Works in 2026
• Can You Get Ozempic Online? How Telehealth Prescriptions Actually Work in 2026
• How to Get Ozempic Online in 2026: The Prescription, Insurance, and Cost Path